Pimozide

This classification denotes an antipsychotic agent with the molecular formula C28H29F2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1HIZ4DL86F, chemically known as 2h-benzimidazol-2-one, 1-(1-(4,4-bis(4-fluorophenyl)butyl)-4-piperidinyl)-1,3-dihydro- but generally known as pimozide, which bears US NIH Compound Identifier 16362. European Medicines Agency schedules Pimozide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09847MIG. The term PIMOZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules pimozide in its Anatomical Therapeutic Chemical (ATC) Classification. PIMOZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pimozide under HS 29333999 and SITC 51574. As of Q4 2014, PIMOZIDE remains the US FDA Preferred Term for this commodity. Pimozide bears US NLM identifiers UMLS ID C0031935 and NCI Concept Code C47672. SMILES: FC1CCC(C(CCCN2CCC(N3C4C([NH]C3=O)CCCC4)CC2)C2CCC(F)CC2)CC1.